22.418 articles found

[Speech therapy for the dysarthria of Parkinson's disease].

Ozsancak C, Auzou P.

Rev Neurol (Paris) · 2005-09-01

DOI: 10.1016/s0035-3787(05)85150-1PMID: 16244572

Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.

Kitagawa M, Tashiro K.

Intern Med · 2005-09-01

DOI: 10.2169/internalmedicine.44.939PMID: 16258207

[The diagnostic and therapeutic application of transcranial magnetic stimulation].

Derejko M, Niewiadomska M, Rakowicz M.

Neurol Neurochir Pol · 2005-09-01

PMID: 16273463

[Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis].

Katunina EA.

Eksp Klin Farmakol · 2005-09-01

PMID: 16277203

Optical coherence tomography in the diagnosis and treatment of neurological disorders.

Jafri MS, Farhang S, Tang RS, Desai N, Fishman PS, Rohwer RG, Tang CM, Schmitt JM.

J Biomed Opt · 2005-09-01

DOI: 10.1117/1.2116967PMID: 16292951

[Observation on therapeutic effect of herbs-partitioned moxibustion on Parkinson disease of 54 cases].

Zhang JF, Sun GS, Zhao GH.

Zhongguo Zhen Jiu · 2005-09-01

PMID: 16318144

[Effects of different doses of levodopa on paraquat-induced neurotoxicity: an experiment with mice].

Du YL, Liu ZG, Chen SD, Lu GQ.

Zhonghua Yi Xue Za Zhi · 2005-09-01

DOI: 10.3760/j:issn:0376-2491.2005.34.007PMID: 16321246

Zonisamide: review of its use in epilepsy therapy.

Zareba G.

Drugs Today (Barc) · 2005-09-01

DOI: 10.1358/dot.2005.41.9.921095PMID: 16341290

The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease.

Willis GL.

Drug News Perspect · 2005-09-01

DOI: 10.1358/dnp.2005.18.7.939349PMID: 16362083

Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration.

Richard IH, Frank S, LaDonna KA, Wang H, McDermott MP, Kurlan R.

Neuropsychiatr Dis Treat · 2005-09-01

PMID: 18568104

USE OF METHYL PYRUVATE OR METHYL PYRUVIC ACID FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND FOR PROTECTING A HUMAN CENTRAL NERVOUS SYSTEM AGAINST NEURONAL DEGENERATION CAUSED BY DEFECTIVE INTRACELLULAR ENERGY PRODUCTION

ANTOSH Stanley C., MEDURI Anthony J..

· 2005-08-31

USE OF METHYL PYRUVATE OR METHYL PYRUVIC ACID FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM AND FOR PROTECTING A HUMAN CENTRAL NERVOUS SYSTEM AGAINST NEURONAL DEGENERATION CAUSED BY DEFECTIVE INTRACELLULAR ENERGY PRODUCTION

Antosh Stanley C., Meduri Anthony J..

· 2005-08-31